NCT04937829View on ClinicalTrials.gov

A Study to Test How Well Different Doses of BI 1569912 Are Tolerated and How Well They Work in People With Depression Who Take Anti-depressive Medication

PHASE1CompletedINTERVENTIONAL
Enrollment

59

Participants

Timeline

Start Date

July 20, 2021

Primary Completion Date

November 16, 2023

Study Completion Date

November 16, 2023

Conditions
Depressive Disorder, Major
Interventions
DRUG

BI 1569912

BI 1569912

DRUG

Placebo

Placebo

Trial Locations (10)

30030

iResearch Atlanta, Decatur

33135

Optimus U Corporation, Miami

33334

Research Centers of America, Oakland Park

44720

Neuro-Behavioral Clinical Research, North Canton

75080

Pillar Clinical Research, LLC, Richardson

75115

InSite Clinical Research, DeSoto

90504

Collaborative Neuroscience Research, LLC, Torrance

92845

Collaborative Neuroscience Network, LLC (CNS), Garden Grove

08009

Hassman Research Institute, Berlin

08053

Hassman Research Institute, Marlton

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT04937829 - A Study to Test How Well Different Doses of BI 1569912 Are Tolerated and How Well They Work in People With Depression Who Take Anti-depressive Medication | Biotech Hunter | Biotech Hunter